Cantargia AB ( (SE:CANTA) ) has provided an update.
Cantargia AB has announced new preclinical data demonstrating that targeting IL1RAP can effectively inhibit tumor-induced systemic immune suppression, potentially overcoming resistance to immune therapy in cancer treatment. The findings, published in Cancer Discovery, show that nadunolimab can reduce immunosuppressive cells and enhance the efficacy of cancer vaccines, highlighting its potential to improve immunotherapy outcomes, particularly in pancreatic and non-small cell lung cancer patients.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform based on the IL1RAP protein, which is involved in various cancer forms and inflammatory diseases. Cantargia’s primary clinical focus is on pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer, with its lead product, nadunolimab (CAN04), being studied in combination with chemotherapy.
YTD Price Performance: -2.61%
Average Trading Volume: 2,500
Technical Sentiment Signal: Buy
Current Market Cap: €36.77M
See more data about CANTA stock on TipRanks’ Stock Analysis page.